Laddar...
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatme...
Sparad:
| I publikationen: | Front Oncol |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Frontiers Media S.A.
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7239024/ https://ncbi.nlm.nih.gov/pubmed/32574277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00862 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|